Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingMETXF 14 EV-to-OCF is -46.45 as of Aug. 26, 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, ME Therapeutics Holding ranks better than 91.27% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ME Therapeutics Holding's Enterprise Value is $40.88 Mil.
ME Therapeutics Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 was $-0.88 Mil. Therefore, ME Therapeutics Holding's EV-to-OCF for today is -46.45.
The historical rank and industry rank for ME Therapeutics Holding's EV-to-OCF or its related term are showing as below:
METXF'
s EV-to-OCF Range Over the Past 10 Years
Min: -46.61 Med: 0 Max: -46.61
Current: -46.61
During the past 4 years, the highest EV-to-OCF of ME Therapeutics Holding was -46.61. The lowest was -46.61. And the median was .
METXF's EV-to-OCF is ranked better than 91.27% of 1409
companies
in the Biotechnology industry
Industry Median: -3.71
vs METXF: -46.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ME Therapeutics Holding (OTCPK:METXF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ME Therapeutics Holding's PE Ratio (TTM) for today is calculated as:
ME Therapeutics Holding's share price for today is $3.25.
ME Therapeutics Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's EV-to-OCF falls into.
ME Therapeutics Holding's current Enterprise Value is $40.88 Mil.
ME Therapeutics Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (METXF) has a EV-to-OCF of -46.45 as of Aug. 26, 2026. According to the industry distribution chart, ME Therapeutics Holding ranks #123 out of 1409 companies in the Biotechnology industry, placing it in the top 8.7%.
Is ME Therapeutics Holding's EV-to-OCF too high?
ME Therapeutics Holding's current EV-to-OCF is -46.45. Based on the distribution chart, ME Therapeutics Holding ranks #123 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #123 out of 1409 companies for EV-to-OCF. This places ME Therapeutics Holding in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ME Therapeutics Holding's current EV-to-OCF is -46.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current EV-to-OCF of -46.45. The current EV-to-OCF is -46.45. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current EV-to-OCF is -46.45 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for METXF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
METXF has been successfully added to your 
